🇺🇸 FDA
Patent

US 8883135

Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor

granted A61KA61K31/496A61K45/06

Quick answer

US patent 8883135 (Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/496, A61K45/06, A61P, A61P31/14